SCHEMBL541609

SCHEMBL541609

O=C(c1cnc(N[C@H]2C[C@H]3CC[C@@H]2C3)nc1C(F)(F)F)N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.42
▸ AURKB Q96GD4 1/20 0.42
▸ SYK P43405 1/20 0.41
▸ LRRK2 Q5S007 7/20 0.41
▸ CYP2D6 P10635 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ CXCR4 P61073 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ SCD O00767 1/20 0.38
▸ HRH4 Q9H3N8 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ GABBR2 O75899 2/20 0.38
▸ GABBR1 Q9UBS5 2/20 0.38
▸ CTSK P43235 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525301 1.00 KDR (0.42) KDRAURKBSYKLRRK2CYP2D6
SCHEMBL6525303 1.00 KDR (0.42) KDRAURKBSYKLRRK2CYP2D6
SCHEMBL541610 1.00 KDR (0.42) KDRAURKBSYKLRRK2CYP2D6
SCHEMBL542035 0.90 HSD11B1 (0.43) KDRAURKBSYKLRRK2CNR2
SCHEMBL542036 0.90 HSD11B1 (0.43) KDRAURKBSYKLRRK2CNR2
SCHEMBL15397165 0.89 LRRK2 (0.40) LRRK2CYP2D6CYP2C19CNR2CXCR4
SCHEMBL10145269 0.88 KDR (0.41) KDRAURKBSYKCXCR4SCD
SCHEMBL541731 0.88 KDR (0.41) KDRAURKBCXCR4SCDHRH4
SCHEMBL541084 0.88 KDR (0.41) KDRAURKBSYKCXCR4SCD
SCHEMBL541903 0.88 KDR (0.41) KDRAURKBSYKCXCR4SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 — — US disclosed
US-20130310373-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-21 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
US-8524727-B2 Pyrimidine compound ASTELLAS PHARMA INC. (JP) 2013-09-03 — — US disclosed
EP-2415765-A1 PYRIMIDINE COMPOUND Astellas Pharma Inc. (JP) 2012-02-08 — — EP disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed
US-20110053912-A1 PYRIMIDINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-03-03 — — US disclosed
WO-2010113834-A1 PYRIMIDINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053912-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 KDR 631/4885AURKB 3221/4885SYK 2005/4885
US-20130310373-A1 PYRIMIDINE COMPOUND CNR2, CNR1, P2RY2 KDR 562/4885AURKB 3462/4885SYK 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback